Biocon Biologics launches Semglee, drug to control high blood sugar, in US

To encourage broad patient access to this important medicine, Mylan is offering Semglee at a wholesale acquisition cost (WAC)[1] of $147.98 per package of five (5) 3ml pens and $98.65 per 10ml vial, representing the lowest WAC for any long-acting insulin glargine on the market, said Biocon in a press release.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2EQTHga
via IFTTT